Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01402986 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Tralokinumab in Adults With Asthma
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 689
- Enrollment target
NCT01402986: Completed Phase 2 study, sponsored by MedImmune.
NCT01402986 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 689 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (418% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01402986, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 689 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the addition of tralokinumab to standard asthma medication is effective in the treatment of adults with asthma.
Primary Outcome
Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed or administered by the investigator or healthcare provider; or 2) participant initiation
Interventions
- OTHER Placebo Q2W
- BIOLOGICAL Tralokinumab 300 mg, Q2W
- OTHER Placebo, Q2/4W
- BIOLOGICAL Tralokinumab 300 mg, Q2/4W
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 689 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
What the finished NCT01402986 record still lists
NCT01402986 is an interventional study that assigns participants to a tested intervention. The registered 689 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (418% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo Q2W is the first listed.
NCT01402986 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01402986 about?
NCT01402986 is a clinical study titled "A Safety and Efficacy Study of Tralokinumab in Adults With Asthma". The purpose of this study is to determine whether the addition of tralokinumab to standard asthma medication is effective in the treatment of adults with asthma.
What is the current status of trial NCT01402986?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 689 participants. The study started on 2011-08. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01402986?
The interventions under investigation include: Placebo Q2W (OTHER), Tralokinumab 300 mg, Q2W (BIOLOGICAL), Placebo, Q2/4W (OTHER), Tralokinumab 300 mg, Q2/4W (BIOLOGICAL).
Who is sponsoring clinical trial NCT01402986?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01402986's enrollment target sits among peer trials
689 47th of 2000 higher than 1,954 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00532051 · 690 participants
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
- NCT05184335 · 690 participants · Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- NCT07221149 · 690 participants · Phase 2
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- NCT05750654 · 688 participants · NA
Effectiveness of Small Phlebotomy Tubes in Reducing Blood Transfusions in Adult Medical Intensive Care Unit and Intermediate Care Unit Patients With Anemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia